Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis

References

• Wang JX, Huang XJ, Wu DP, et al. [Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China]. Zhonghua Xue Ye Xue Za Zhi 2009;30:721-5
   PubMedGoogle Scholar
• He QT, Shi FT, Yuan ZZ. Epidemiological investigation of leukemia in Baotou. Inner Mongolia Med J 1993;2:3-5
   Google Scholar
• Hu JL, Mao Z, Dong DP, et al. Epidemiological investigation of leukemia in 15 years in Haian County. Chin Med J Commun 2004;18:114-15
   Google Scholar
• Tang ZX, Sun QY, Zhang JT, et al. Epidemiological investigation of leukemia in 11 years in the Jinshan district of Shanghai. Zhonghua Xue Ye Xue Za Zhi 1994;15:430
   Google Scholar
• Zhang XY, Zhang DL, Sun X, et al. Epidemiological investigation of leukemia and aplastic anemia in Shenzhen. Zhonghua Xue Ye Xue Za Zhi 2001;22:347
   Google Scholar
• Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009;23:602-4
   PubMed Web of Science ®Google Scholar
• Bian S. Chronic myelogenous leukemia. China Medical Science Press, Beijing. 2003
   Google Scholar
• D’Antonio J. Chronic myelogenous leukemia. Clin J Oncol Nurs 2005;9:535-8
   PubMedGoogle Scholar
• American Cancer Society. Leukemia – Chronic Myeloid (Myelogenous). Atlanta, GA: American Cancer Society, 2008
   Google Scholar
• Hughes TP, Ross DM, Melo JV. Management of patients with chronic myeloid leukemia. Handbook of chronic myeloid leukemia. Switzerland: Springer International Publishing, 2014. pp. 35-51
   Google Scholar
• Chen Z, Wang C, Xu X, et al. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009;12(3Suppl)3:S85-S8
   Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-65.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Xu LP, Liu DH, et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 2013;27:2410-13
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA. [Guideline for management of chronic myeloid leukemia(2016)]. Zhonghua Xue Ye Xue Za Zhi 2016;37:633-9
   PubMedGoogle Scholar
• Tao Z, Liu B, Zhao Y, et al. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib. Leuk Res 2014;38:1030-5
   PubMed Web of Science ®Google Scholar
• Novartis. Oncology Patient Assistance Programs. Novartis Global. https://www.novartis.com/about-us/corporate-responsibility/access-healthcare/global-access-programs/oncology-patient. Accessedon 29 Sep 2016
   Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574-83
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib–a Swedish model application. Acta Oncol 2010;49:851-8
   PubMed Web of Science ®Google Scholar
• Shin M, Shin S, Lee JY, et al. Cost-effectiveness of first-line tyrosine kinase inhibitors (Tkis) in newly diagnosed chronic myeloid leukemia (Cml) patients in Korea: comparison of Dasatinib (100mg), Nilotinib (600mg) and Imatinib (400mg). Value Health 2015;18:A458
   PubMed Web of Science ®Google Scholar
• Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report–Part I. Value Health 2010;13:3-7
   PubMed Web of Science ®Google Scholar
• Introduction. The First Affiliated Hospital of Soochow University Suzhou First People's Hospital. Suzhou, China. http://fyy.sdfyy.cn/Main/Display_B721_A0.html. Accessed on 29 Sep 2016.
   Google Scholar
• Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 2015;125:2771-8
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407
   PubMed Web of Science ®Google Scholar
• WHO. WHO Macroeconomics. Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001
   Google Scholar
• NBS. GDP per capita in China. National Bureau of Statistics of China. Beijing. 2015. http://data.stats.gov.cn/easyquery.htm?cn=C01 Accessed on 29 Sep 2016
   Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Jiang Q, Huang X. CML treatment and development in China. Chin J Intern Med 2013;52:803-5
   PubMedGoogle Scholar
• American Cancer Society. Stem cell transplant for chronic myeloid leukemia. http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-treating-bone-marrow-stem-cell. Accessed on 29 Sep 2016
   Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus lowdose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-46
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515-26
   PubMed Web of Science ®Google Scholar
• NICE. National Institute for Health and Care Excellence. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia. Technology appraisal guidance. London. 2012. http://www.nice.org.uk/guidance/ta251 Accessed on 29 Sep 2016
   Google Scholar
• NICE. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241). London. 2012. http://www.nice.org.uk/guidance/ta241 Accessed on 29 Sep 2016.
   Google Scholar
• NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. London. 2009. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf Accessed on 29 Sep 2016
   Google Scholar
• Gao GL, Xu N, Zhou X, et al. Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase. Natl Med J China 2013;93:3035-9
   Google Scholar
• Jin H, Han Y, Zhang Y. Clinical observation of imatinib in treatment of patients with chronic myeloid leukemia. Chin J Trauma Disabil Med 2015;23:23-4
   Google Scholar
• Meng Y, Liu CS, Li W, et al. Efficacy analysis of imatinib in treatment of patients with chronic myeloid leukemia. J Jilin Uni (Med Ed) 2012;38:563-6
   Google Scholar
• Wu RJ, Xie HL. Clinical observation of interferon combined with chemotherapy and imatinib in the treatment of chronic myeloid leukemia. Chin J Convalesc Med 2014;5:430-1
   Google Scholar
• Yang DD, Zhang J. Efficacy analysis of the application of imatinib combined with hydroxyurea and interferon in the treatment of chronic myeloid leukemia. Contemp Med Forum 2015;13:156-8
   Google Scholar
• Zhou M, Sha XS, Chou HY, et al. Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Chin J Hematol 2014;35:126-8
   Google Scholar
• Zou WY, Xu DR, Su C, et al. Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects. J Southern Med Uni 2008;28:1660-2
   Google Scholar